GlassScriptPhysician profile
Adam L Edwards
NPI 1649560806
$4,072.53
in general payments reported to CMS, 2019-2025
26 companies · $1,969 in 2025
The $1,969 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2023: $400 · 2024: $1,590 · 2025: $1,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,932 · Gift: $27.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,932.17 |
| Gift | $27.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,033.78 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $627.01 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $436.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $248.49 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.63 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Medtronic, INC. | $179.94 | 2023-2025 | Interstim, Endoflip |
| Ardelyx, INC. | $173.89 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $173.62 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.32 | 2024-2025 | Entyvio, Gattex |
| Pfizer INC. | $110.84 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $92.17 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $74.78 | 2025 | |
| Conmed Corporation | $67.46 | 2025 | Conmed Biliary |
| Merck Sharp & Dohme LLC | $63.59 | 2023-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $63.20 | 2025 | Iqirvo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $62.89 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $60.38 | 2024-2025 | Vowst, Zenpep |
| Evoke Pharma, INC. | $46.06 | 2025 | |
| Braintree Laboratories, INC. | $41.37 | 2023-2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $36.86 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $21.52 | 2025 | Dupixent |
| Orphalan INC | $18.27 | 2024 | Cuvrior |
| Ironwood Pharmaceuticals, INC | $16.97 | 2024 | |
| Novo Nordisk INC | $15.39 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $14.19 | 2024 | Idacio |
| Ferring Pharmaceuticals INC. | $12.84 | 2023 | Cimzia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.